SCHEMBL2397070

SCHEMBL2397070

O=C(O)[C@H](Cl)Cc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.61
ALPI P09923 1/20 0.57
PKM P14618 1/20 0.57
PTGS1 P23219 1/20 0.57
XIAP P98170 1/20 0.57
SLC7A5 Q01650 1/20 0.57
CPA1 P15085 4/20 0.53
CPA3 P15088 3/20 0.53
FOLH1 Q04609 1/20 0.53
CPB1 P15086 1/20 0.53
CPB2 Q96IY4 1/20 0.53
SRR Q9GZT4 2/20 0.52
SLC1A3 P43003 2/20 0.52
SLC1A2 P43004 2/20 0.52
SLC1A1 P43005 2/20 0.52
NPSR1 Q6W5P4 1/20 0.50
HSD17B10 Q99714 1/20 0.50
MDM2 Q00987 1/20 0.50
AKR1B1 P15121 1/20 0.50
PPARG P37231 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7483692 1.00 CYP1A2 (0.61) CYP1A2ALPIPKMPTGS1XIAP
SCHEMBL1566396 1.00 CYP1A2 (0.61) CYP1A2ALPIPKMPTGS1XIAP
Hydrochloric Acid SCHEMBL6054521 0.98 CYP1A2 (0.59) CYP1A2ALPIPKMPTGS1XIAP
SCHEMBL6958621 0.86 CYP1A2 (0.56) CYP1A2ALPIPKMPTGS1XIAP
SCHEMBL6054519 0.84 CYP1A2 (0.54) CYP1A2ALPIPKMPTGS1XIAP
SCHEMBL11859970 0.84 CYP1A2 (0.54) CYP1A2ALPIPKMPTGS1XIAP
SCHEMBL11663421 0.83 PPARG (0.65) CYP1A2PTGS1PPARGPPARA
SCHEMBL133927 0.83 PPARG (0.56) PPARGPPARA
SCHEMBL4803142 0.83 SLC7A5 (0.60) SLC7A5FOLH1
SCHEMBL5763729 0.83 EPHX1 (0.58) CYP1A2ALPIPKMPTGS1XIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130274470-A1 Triazolium Carbene Catalysts and Stereoselective Bond Forming Reactions Thereof NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2013-10-17 US disclosed
US-20130274470-A1 Triazolium Carbene Catalysts and Stereoselective Bond Forming Reactions Thereof NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2013-10-17 US disclosed
US-20130274470-A1 Triazolium Carbene Catalysts and Stereoselective Bond Forming Reactions Thereof NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2013-10-17 US disclosed
US-20110224431-A1 Triazolium Carbene Catalysts and Stereoselective Bond Forming Reactions Thereof COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2011-09-15 US disclosed
US-20110224431-A1 Triazolium Carbene Catalysts and Stereoselective Bond Forming Reactions Thereof COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2011-09-15 US disclosed
US-20060247470-A1 Process for producing optically active carboxylic acid substituted in 2-position KANEKA CORPORATION 2006-11-02 US disclosed
US-7094926-B2 Process for producing optically active carboxylic acid substituted in 2-position KANEKA CORPORATION (JP) 2006-08-22 US disclosed
US-20030144546-A1 Process for producing optically active carboxylic acid subtituted in 2-position KANEKA CORPORATION (JP) 2003-07-31 US disclosed
US-20030013903-A1 Process for crystallization of 2-acetylthio-3-phenyl-propionic acid KANEKA CORPORATION (JP) 2003-01-16 US disclosed
EP-1275642-A1 PROCESS FOR CRYSTALLIZATION OF 2-ACETYLTHIO-3-PHENYL-PROPIONIC ACID KANEKA CORPORATION (JP) 2003-01-15 EP disclosed
EP-1251115-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE CARBOXYLIC ACID SUBSTITUTED IN 2-POSITION KANEKA CORPORATION (JP) 2002-10-23 EP disclosed
EP-1091958-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2001-04-18 EP disclosed
WO-2000001692-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2000-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130274470-A1 Triazolium Carbene Catalysts and Stereoselective Bond Forming Reactions Thereof HDHD5, DCX, CLK2 CYP1A2 1524/4885ALPI 4763/4885PKM 3559/4885
US-20030144546-A1 Process for producing optically active carboxylic acid subtituted in 2-position HAO2, CA2, HACL2 CYP1A2 1015/4885ALPI 1743/4885PKM 3646/4885
US-20110224431-A1 Triazolium Carbene Catalysts and Stereoselective Bond Forming Reactions Thereof HDHD5, DCX, CLK2 CYP1A2 1524/4885ALPI 4763/4885PKM 3559/4885
US-20060247470-A1 Process for producing optically active carboxylic acid substituted in 2-position HAO2, CA2, HACL2 CYP1A2 603/4885ALPI 969/4885PKM 3421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.